其它别名(2Z)-2-Cyano-3-(3,4-Dihydroxy-5-Nitrophenyl)-N,N-Diethyl-2-Propenamide; (Z)-Entacapone; Cis-Entacapone; Entacapone Impurity A -I; (Z)-2-Cyano-3-(3,4-Dihydroxy-5-Nitrophenyl)-N,N-Diethylprop-2-Enamide; Entacapone Impurity 17(Entacapone Ep Impurity A); Entacapone Related Compound A (25 Mg) ((Z)-2-Cyano-3-(3,4-Dihydroxy-5-Nitrophenyl)-N,N-Diethylacrylamide); Entacapone Ep Impurity A
专利号:WO-2008098960-A1 优先权日:2007-02-13 标 题:Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form
专利号:US-2009326062-A1 优先权日:2007-02-13 标 题 :Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form
1. Wikberg, T., Vuorela, A., Ottoila, P., et al. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. 21(1), 81-92 (1993). 2. Tekale, P., Tekale, S., and Mhatre, V.S. Determination of impurities in formulated form of entacapone by RP-HPLC method. Der Pharma Chemica 3(5), 63-68 (2011). 3. Soukhova, N.S., Kassymbek, Z., Bradby, S., et al. Development of characterization methods for entacapone in a pharmaceutical bulk. J. Pharm. Biomed. Anal. 54(4), 860-865 (2011).
合成参考文献
摘要:S113 | SWISSPHARMA24 | 2024 Swiss Pharmaceutical List with Metabolites | DOI:10.5281/zenodo.10501043